Get updates by email
Topics
Contributors
- Sanford L. Michelman
- Matthew R. Lasky
- Robert P. Barbarowicz
- T. Darren Barker
- Robert N. Berg
- Ronald R. Camhi
- Peter F. Cifichiello
- Jesse Contreras
- Robert D. Estrin
- Jeffrey D. Farrow
- Taylor C. Foss
- Samantha Gavin
- Kelly M. Hagemann
- Janeen R. Hall
- Mona Z. Hanna
- David F. Hauge
- Ryan Hong
- Marc R. Jacobs
- Robin James
- Warren A. Koshofer
- Dana A. Kravetz
- Jesse S. Krompier
- Vincent S. Loh
- Kathryn T. Lundy
- Scott T. Lyon
- Jennifer A. Mauri
- Kathleen M. McCain
- Amanda K. Pawlyk
- Michael S. Poster
- Eric J. Rans
- Jeremy D. Richardson
- Mark B. Robinson
- Ian Shane
- Lara A. H. Shortz
- Adam Z. Solomon
- Justin A. Stein
- Peter L. Steinman
- Todd H. Stitt
- Stacey L. Zill
- Marc B. Zimmerman
Archives
Contact
Paul Zimmerman
pzimmerman@mrllp.com
310.299.5500
Showing 1 post by Jennifer A. Mauri.
studiom1 © 123RF.com
A Different Route: Challenging Orange Book Patents Via Inter Partes Review
Since the passage of the America Invents Act (AIA) in 2012, and the corresponding implementation of the inter partes review (IPR) process, patent challengers have been utilizing the Patent Trial and Appeal Board (PTAB) as an alternative venue for patent adjudication. The IPR process permits anyone other than the patent owner to challenge a patent's validity for alleged obviousness or lack of novelty based on patents or printed publications. This has become an increasingly popular avenue for challenging “orange book” pharmaceutical patents, many of which are simultaneously at issue in Hatch-Waxman / Abbreviated New Drug Application (ANDA) litigation in the federal courts. (Read More)